title: Golgi protein 73(GP73), a useful serum marker in liver diseases.
abstract: BACKGROUND
  This study was performed to quantify the expression of Golgi protein-73 (GP73) in healthy controls and in patients with liver disease, and to evaluate the correlations between GP73 and other serum markers in different liver diseases.
  
  
  METHODS
  Serum GP73 was measured in 478 healthy controls and 296 patients with different types of liver disease. Quantitative hepatitis B virus (HBV) DNA was determined in two chronic hepatitis B (CHB) groups. Other serum liver fibrosis markers were measured in the liver fibrosis group and α-fetoprotein (AFP) was measured in hepatocellular carcinoma (HCC) group. The correlations between GP73 and these markers were evaluated.
  
  
  RESULTS
  The GP73 value in hepatitis B e antigen (HBeAg)-positive CHB group, HBeAg-negative CHB group, liver fibrosis group and HCC group was significantly higher (p<0.001) than that in healthy controls. GP73 showed significant correlation with other markers in the liver fibrosis group and with AFP in the HCC group.
  
  
  CONCLUSIONS
  Compared with healthy controls, GP73 in patients with liver disease was significantly increased. With the progression of liver disease, GP73 showed a significantly increasing trend. These results suggest that GP73 might be used as a serum marker for the diagnosis of liver diseases and for monitoring disease progression.
authors.affiliation: Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, P.R. China.
authors.forename: Xiangyi
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, P.R. China.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Wan
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, P.R. China.
authors.forename: Zhongwu
authors.initials: Z
authors.lastname: Li
authors.affiliation: Hotgen Biotechnology Co. Ltd., Beijing, P.R. China.
authors.forename: Changqing
authors.initials: C
authors.lastname: Lin
authors.affiliation: Department of Gastroenterology, Beijing Tongren Hospital, Capital Medical University, Beijing, P.R. China.
authors.forename: Yutao
authors.initials: Y
authors.lastname: Zhan
authors.affiliation: Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, P.R. China.
authors.forename: Xinxin
authors.initials: X
authors.lastname: Lu
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000175:diagnosis; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis; D008107:Liver Diseases / Q000097:blood* / Q000175:diagnosis; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis; D008297:Male; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000906:Antibodies; D015415:Biomarkers; D004279:DNA, Viral; C410824:GOLM1 protein, human; D006513:Hepatitis B e Antigens; D008565:Membrane Proteins; D000509:alpha-Fetoproteins